Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 ARROW study subgroup analysis

DSpace Repository

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 ARROW study subgroup analysis

Author: Dimopoulos, Meletios A.; Niesvizky, Ruben; Weisel, Katja; Siegel, David S.; Hajek, Roman; Mateos, Maria-Victoria; Cavo, Michele; Huang, Mei; Zahlten-Kumeli, Anita; Moreau, Philippe
Tübinger Autor(en):
Weisel, Katja
Published in: Blood Cancer Journal (2020), Bd. 10, Article 35
Verlagsangabe: Nature Publishing Group
Language: English
Full text: http://dx.doi.org/10.1038/s41408-020-0300-y
ISSN: 2044-5385
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)